Related Experiment Video
Updated: Mar 17, 2026
In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
Published on: August 1, 2025
L-asparaginase in the treatment of patients with acute lymphoblastic leukemia
Rachel A Egler1, Sanjay P Ahuja1, Yousif Matloub1
1Department of Pediatric Hematology/Oncology, Case Western Reserve University School of Medicine, Rainbow Babies and Children's Hospital, Cleveland, OH, USA.
Insights
L-asparaginase is crucial for treating acute lymphoblastic leukemia (ALL). Switching to Erwinia asparaginase can improve outcomes for patients experiencing hypersensitivity reactions to E. coli-derived treatments.
Area of Science:
- Hematology
- Pediatric Oncology
- Pharmacology
Background:
- Acute lymphoblastic leukemia (ALL) is a common childhood cancer.
- L-asparaginase is a key component in ALL treatment, significantly improving pediatric survival rates.
- Adolescent and young adult (AYA) ALL patients historically have poorer outcomes, but pediatric-inspired protocols show promise.
Purpose of the Study:
- To review the role of L-asparaginase in ALL treatment.
- To discuss the challenges of hypersensitivity reactions to E. coli-derived asparaginase.
- To highlight the efficacy of Erwinia chrysanthemi asparaginase in AYA patients.
Main Methods:
- Review of existing literature on L-asparaginase in ALL treatment.
- Analysis of pharmacokinetic profiles and hypersensitivity reactions.
- Evaluation of outcomes for patients treated with different asparaginase formulations.
Main Results:
- Increased cumulative asparaginase doses in pediatric-inspired protocols improve AYA ALL survival.
- Up to 30% of patients experience hypersensitivity to E. coli-derived pegylated asparaginase.
- Erwinia asparaginase offers an alternative for hypersensitive patients, achieving similar outcomes with adequate dosing.
Conclusions:
- Erwinia asparaginase is an effective alternative for ALL patients with hypersensitivity to E. coli-derived agents.
- Optimized dosing and therapeutic drug monitoring are essential for Erwinia asparaginase efficacy.
- Improved treatment strategies, including alternative asparaginases, are crucial for enhancing ALL patient survival, particularly in AYA populations.
Abstract:
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy that predominantly occurs in children between 2 and 10 years of age. L-asparaginase is an integral component of treatment for patients with ALL and since its introduction into pediatric treatment protocols in the 1960s, survival rates in children have progressively risen to nearly 90%. Outcomes for adolescent and young adult (AYA) patients, aged 15-39 years and diagnosed with ALL, have historically been less favorable. However, recent reports suggest substantially increased survival in AYA patients treated on pediatric-inspired protocols that include a greater cumulative dose of asparaginase. All currently available asparaginases share the same mechanism of action - the deamination and depletion of serum asparagine levels - yet each displays a markedly different pharmacokinetic profile. Pegylated asparaginase derived from the bacterium Escherichia coli is used as first-line therapy; however, up to 30% of patients develop a treatment-limiting hypersensitivity reaction. Patients who experience a hypersensitivity reaction to an E. coli-derived asparaginase can continue treatment with Erwinia chrysanthemi asparaginase. Erwinia asparaginase is immunologically distinct from E. coli-derived asparaginases and exhibits no cross-reactivity. Studies have shown that with adequate dosing, therapeutic levels of Erwinia asparaginase activity can be achieved, and patients switched to Erwinia asparaginase due to hypersensitivity can obtain outcomes similar to patients who do not experience a hypersensitivity reaction. Therapeutic drug monitoring may be required to ensure that therapeutic levels of asparaginase activity are maintained.
